ACCC COVID-19 Resource Center & Discussion Group
for Insights on Providing Optimal Patient Care During the Pandemic.
Providing a VOICE for Tennessee's MULTIDISCIPLINARY CANCER CARE TEAMS and the PATIENTS THEY SERVE since 1990
Meetings & Education
State Society Education Series
Articles and Blogs
State & Federal Resources
Find A Clinical Trial
Off-Label Use Literature
Patient Advocacy Organizations
National Professional Organizations
Financial Advocacy & Patient Assistance
TOPS Advocacy Support
TOPS Corporate Members
Become a Corporate Member
Industry News Archive
COVID-19 Featured Resources
FDA Approves Selinexor for Multiple Myeloma
On July 3, 2019, the U.S. Food and Drug Administration (FDA) granted accelerated approval to selinexor (Xpovio, Karyopharm Therapeutics) in combination with dexamethasone for adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody.
As a condition of accelerated approval, further clinical trials may be required to verify and describe selinexor’s benefit. FDA granted this application fast track designation and orphan drug designation.
Read FDA announcement